# Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

> **NCT02103894** · PHASE1 · COMPLETED · sponsor: **Molecular NeuroImaging** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer's Disease (AD)
- Parkinson's Disease (PD)
- Chronic Traumatic Encephalopathy (CTE)
- Progressive Supranuclear Palsy (PSP)
- Frontal Temporal Dementia (FTD)
- Pick's Disease
- Tauopathies

## Interventions

- **DRUG:** [18F]T807 ([18F]MNI-777)

## Key facts

- **NCT ID:** NCT02103894
- **Lead sponsor:** Molecular NeuroImaging
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103894, "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02103894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*